UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 24, 2011
Bacterin International Holdings, Inc.
|
(Exact Name of Registrant as Specified in Its Charter)
|
|
Delaware
|
|
(State or Other Jurisdiction of Incorporation)
|
|
001-34951
|
20-5313323
|
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
600 Cruiser Lane
Belgrade, Montana
|
59714
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
(406) 388-0480
|
|
(Registrant’s Telephone Number, Including Area Code)
|
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
The Company has issued press releases entitled “Bacterin Awarded Approved Vendor Status for American Medical Concepts’ Network of Hospitals in the Northwest U.S.” and “Bacterin to Present at Sixth Annual Singular Research ‘Best of the Uncovereds’ Conference on October 26, 2011” which are attached as Exhibits 99.1 and 99.2 and incorporated herein.
The information in this Item 7.01 and the documents attached as Exhibit 99.1 and 99.2 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No
|
Description
|
|
|
|
||
|
99.1
|
Press Release of Bacterin International Holdings, Inc. dated October 24, 2011 entitled “Bacterin Awarded Approved Vendor Status for American Medical Concepts’ Network of Hospitals in the Northwest U.S.”
|
|
|
99.2
|
Press Release of Bacterin International Holdings, Inc. dated October 24, 2011 entitled “Bacterin to Present at Sixth Annual Singular Research ‘Best of the Uncovereds’ Conference on October 26, 2011”
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: October 24, 2011
|
BACTERIN INTERNATIONAL HOLDINGS, INC.
|
|
|
By:
|
/s/ Guy S. Cook
|
|
|
Name: Guy S. Cook
|
||
|
Title: President and Chief Executive Officer
|
||
EXHIBIT INDEX
|
99.1
|
Press Release of Bacterin International Holdings, Inc. dated October 24, 2011 entitled “Bacterin Awarded Approved Vendor Status for American Medical Concepts’ Network of Hospitals in the Northwest U.S.”
|
|
|
99.2
|
Press Release of Bacterin International Holdings, Inc. dated October 24, 2011 entitled “Bacterin to Present at Sixth Annual Singular Research ‘Best of the Uncovereds’ Conference on October 26, 2011”
|
BacterinAwarded Approved Vendor Status for American Medical Concepts’ Network of Hospitals in the Northwest U.S.
BELGRADE, MT, – October24, 2011 – Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications,has been awarded approved vendor status byAmerican Medical Concepts (AMC), the largest multi-specialty Orthopedic, Spine and Neuro distribution company in the Northwest region of the U.S.
The award gives Bacterin ‘pre-approved,’ ready-access to market its full portfolio of products, including the existing Cranio-maxillofacial (CMF) line of orthopedic implants as well as the pending sustained release antimicrobial coatings and device implants, to AMC’s entire network of hospitals andfreestanding surgery centers.
“Our pre-approved status with AMC opens the door to a leading healthcare delivery networkthat is dominate in the Northwest. We are pleased to partner with such a prestigious group as AMC to distribute our current and future products,” said Guy Cook, Bacterin’schairman and CEO.
Rob Goodman, co-founder of AMC, commented: “We’re excited to add Bacterin into our portfolio of products, and we expect Bacterin’s products to be well received by our accounts across the region.This includes Bacterin’sQuickScrew™, theirunique pre-loaded surgical screw delivery system for CMF procedures,which provides a new level of speed and convenience during surgery.”
Added Cook:“For more than 20 years, AMChas beendedicated to providing the best patient care by delivering quality equipment and medical supplies. Their endorsement is a strong validation of ourcurrent biologic portfolio and future product pipeline.”
About American Medical Concepts
American Medical Concepts, Inc. distributes orthopedic and spinal implant devices in the Northwest United States. The company provides medical, surgical, prosthetic, and orthopedic devices for the spine, knees, hips, trauma and biologics. The company was founded in 1992 with its main distribution center in Portland, Oregon. AMC has offices in Portland, Seattle, WA, AK, ID and HI and runs its financial services in Eugene, OR. For further information, please visit www.americanmedical.com.
1
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE Amex: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.
Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.
Company Contact:
Guy Cook
President & CEO
Bacterin International Holdings, Inc.
Tel 406-388-0480
gcook@bacterin.com
Investor Relations:
Liolios Group, Inc.
Scott Liolios or Ron Both
Tel 949-574-3860
info@liolios.com
2
BELGRADE, MT, – October 24, 2011 – Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, has been invited to present at the Singular Research’s Sixth Annual ‘Best of the Uncovereds’ Conference. The conference will be held at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
Bacterin’s chairman and CEO Guy Cook is scheduled to present on Wednesday, October 26, 2011 at 2:30 p.m. Eastern time, with one-on-one meetings held throughout the day. Management will discuss the company’s business plan and objectives for the remainder of 2011.
The presentation will be available via webcast at http://www.singularresearch.com/.
A replay link will also be available for 90 days following the live presentation on the company’s website at www.bacterin.com.
Bacterin reported record revenue for the second quarter 2011 of $7.5 million, up 25% sequentially and 135% year-over-year. These results also drove its first positive EBITDA quarter.
For more information about the conference or to schedule a one-on-one meeting with Bacterin management, contact your Singular Research representative.
About Singular Research
Singular Research aims to be the most trusted supplier of independent, trusted, single-source research on small-to-micro cap companies to the small-to-medium sized Hedge Fund manager. Singular’s analysts research companies that are typically not covered by any other firms. Analysts are compensated based on the accuracy of their research calls not through trading commissions or investment banking fees. For more information, visit www.singular-research.com/index.htm.
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE Amex: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.
1
Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.
Company Contact:
Guy Cook
President & CEO
Bacterin International Holdings, Inc.
Tel 406-388-0480
gcook@bacterin.com
Investor Relations:
Liolios Group, Inc.
Scott Liolios or Ron Both
Tel 949-574-3860
info@liolios.com
2